NCT03843658

Identifying Novel Biomarkers in Early Rheumatology Patients

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 300 (estimated)
• Sponsor: Arthritis Northwest PLLC · Industry
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

Patients new to a rheumatology practice will be asked if they want to consent to their blood sample, medical records, and hand/foot x-rays (with sharp scores) for the analysis and correlation with the diagnosis they will receive from the rheumatologist.

Detailed description

At the end of their first visit new rheumatology patients will be asked for their interest in joining the Inova biomarker study. If yes, the patient will be consented, blood will be drawn for the Inova biomarkers, and x-rays will be sent for sharp scoring. Patients may decline and will not be part of the Inova study. Patients who decline will continue to receive standard of care treatment henceforth. Patients in the Inova trial will receive a diagnosis from their doctor and are placed into separate cohorts based upon their diagnosis. The Inova biomarker results of each cohort will be cross-correlated with diagnoses, pre-screening tool results. Baseline disease activity and sharp scores will also be correlation variables.

Conditions

• Rheumatologic Disorder

Interventions

Type	Name	Description
OTHER	There is no intervention, but a diagnosis.	Cohorts will be determined by the primary rheumatology diagnosis.

Timeline

• Start date: 2019-03-15
• Primary completion: 2020-03-15
• Completion: 2020-09-15
• First posted: 2019-02-18
• Last updated: 2019-02-18